CYBN CYBIN INC.

NYSE cybin.com


$ 6.03 $ -0.07 (-1.15 %)    

Friday, 17-Oct-2025 18:04:04 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 6.03
$ 6.03
$ 6.00 x 10
$ 6.36 x 6
$ 5.81 - $ 6.10
$ 4.81 - $ 13.88
694,137
na
130.26M
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-sugge...

Core News & Articles

https://www.marijuanamoment.net/new-york-lawmakers-hold-hearing-psilocybins-medical-benefits-amid-broader-debate-over-psychedel...

 cybin-highlights-neuropsychiatry-platform-and-upcoming-clinical-milestones-completes-enrollment-of-36-participants-in-phase-2-study-of-cyb004-continues-to-advance-cyb003-the-companys-proprietary-deuterated-psilocin-analog-in-phase-3-studies-for-the-adjunctive-treatment-of-major-depressive-disorder-dosing-is-ongoing-in-the-first-pivotal-study-approach--with-expected-enrollment-of-220-patients-across-45-us-clinical-sites

- Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company's deuterated dimethyltryptam...

 cybin-cuts-size-of-mixed-shelf-offering-to-up-to-800m-from-up-to-10b

-SEC Filing

Core News & Articles

https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/

 cybin-names-co-founder-eric-so-as-interim-ceo-as-doug-drysdale-steps-down

Cybin Inc. (NYSE:CYBN) (Cboe Canada:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychi...

Core News & Articles

https://www.marijuanamoment.net/military-to-start-testing-service-members-for-the-psychedelic-psilocin-memo-shows/

Core News & Articles

https://www.marijuanamoment.net/gop-senator-is-confident-psychedelics-access-will-expand-under-trump-saying-many-veterans-speak...

Core News & Articles

https://www.marijuanamoment.net/u-s-senate-committee-to-hold-hearing-on-benefits-of-psychedelics-for-military-veterans/

 cybins-clinical-trial-application-approved-by-irish-medicines-board-to-initiate-embrace-study-in-ireland-poland-and-greece

- EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical site...

Core News & Articles

https://www.marijuanamoment.net/massachusetts-psychiatric-society-endorses-bill-to-decriminalize-psilocybin-possession/

Core News & Articles

https://www.marijuanamoment.net/california-governor-hes-all-in-on-psychedelic-therapy-access-but-worries-about-capitalists-comm...

Core News & Articles

https://www.washingtonpost.com/health/2025/07/16/psychedelics-rfk-jr-kennedy-ibogaine-mdma/41658b06-6246-11f0-bf70-56d8888ebb94...

Core News & Articles

https://www.foxnews.com/health/key-living-longer-could-tied-surprising-substance-study-suggests

 canaccord-genuity-maintains-buy-on-cybin-lowers-price-target-to-70

Canaccord Genuity analyst Sumant Kulkarni maintains Cybin (AMEX:CYBN) with a Buy and lowers the price target from $73 to $70.

 cybin-raises-50m-in-convertible-debenture-private-placement-with-potential-500m-total-funding-with-high-trail-special-situations

- Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company fo...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-06-30/colorado-moves-to-allow-hallucinogen-ibogaine-for-medical-use?embedded-check...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION